Blake Borgeson serves as Executive at RECURSION PHARMACEUTICALS, INC., where they oversee executive responsibilities. Since joining the company, Blake Borgeson has executed 76 insider transactions totaling $8.8M, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 3, 2026 involved selling 220,000 shares valued at $924.0K.
Blake Borgeson currently holds 6,429,863 shares of RECURSION PHARMACEUTICALS, INC. (RXRX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Blake Borgeson has been a net seller of RXRX stock. They have purchased $0 and sold $8.8M worth of shares.
Blake Borgeson's most recent insider trade was on Feb 3, 2026, when they sold 220,000 shares at $4.20 per share.
Get notified when new Form 4 filings are submitted
| $4.36 |
| Discretionary |
| Dec 2, 2025 | RXRX | $961.4K | Sale | 220,000 | $4.37 | Discretionary |
| Sep 17, 2024 | RXRX | $78.3K | Sale | 11,447 | $6.84 | Planned |
| Sep 3, 2024 | RXRX | $71.8K | Sale | 11,447 | $6.27 | Planned |
| Aug 20, 2024 | RXRX | $81.5K | Sale | 11,447 | $7.12 | Planned |
| Aug 6, 2024 | RXRX | $78.1K | Sale | 11,447 | $6.82 | Planned |
| Jul 23, 2024 | RXRX | $97.1K | Sale | 11,447 | $8.48 | Planned |
| Jul 9, 2024 | RXRX | $83.8K | Sale | 11,447 | $7.32 | Planned |
| Jul 1, 2024 | RXRX | $0 | Award | 1,441 | $N/A | Discretionary |
| Jun 25, 2024 | RXRX | $108.9K | Sale | 11,447 | $9.51 | Planned |
| Jun 11, 2024 | RXRX | $96.7K | Sale | 11,447 | $8.45 | Planned |
| Jun 3, 2024 | RXRX | $0 | Award | 13,097 | $N/A | Discretionary |
| May 28, 2024 | RXRX | $105.0K | Sale | 11,447 | $9.17 | Planned |
| May 14, 2024 | RXRX | $202.9K | Sale | 20,054 | $10.12 | Planned |
| Apr 30, 2024 | RXRX | $91.0K | Sale | 11,447 | $7.95 | Planned |
| Apr 16, 2024 | RXRX | $87.7K | Sale | 11,447 | $7.66 | Planned |
| Apr 2, 2024 | RXRX | $101.0K | Sale | 11,447 | $8.82 | Planned |
| Mar 19, 2024 | RXRX | $216.4K | Sale | 20,054 | $10.79 | Planned |
| Mar 5, 2024 | RXRX | $241.9K | Sale | 20,054 | $12.06 | Planned |
| Feb 20, 2024 | RXRX | $243.1K | Sale | 19,745 | $12.31 | Planned |
| Feb 20, 2024 | RXRX | $4.0K | Sale | 309 | $13.04 | Planned |
| Feb 6, 2024 | RXRX | $106.5K | Sale | 11,447 | $9.30 | Planned |
| Jan 23, 2024 | RXRX | $212.2K | Sale | 20,054 | $10.58 | Planned |
| Jan 9, 2024 | RXRX | $83.3K | Sale | 6,303 | $13.21 | Planned |
| Jan 9, 2024 | RXRX | $189.9K | Sale | 13,751 | $13.81 | Planned |
| Dec 26, 2023 | RXRX | $213.2K | Sale | 20,054 | $10.63 | Planned |
| Dec 12, 2023 | RXRX | $84.7K | Sale | 11,447 | $7.40 | Planned |
| Nov 28, 2023 | RXRX | $76.9K | Sale | 11,447 | $6.72 | Planned |
| Nov 14, 2023 | RXRX | $56.2K | Sale | 8,885 | $6.32 | Discretionary |